Tumor Biology

, Volume 36, Issue 4, pp 2893–2905 | Cite as

Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes

  • Rouhallah Najjar Sadeghi
  • Fatemeh Karami-Tehrani
  • Siamak Salami
Research Article

Abstract

Glycolysis has been shown to be required for the cell growth and proliferation in several cancer cells. However, prostate cancer cells were accused of using more fatty acid than glucose to meet their bioenergetic demands. The present study was designed to evaluate the involvement of hexokinase and CPT-1 in the cell growth and proliferation of human prostate cancer cell lines, PC3, and LNCaP-FGC-10. Hexokinase and CPT-1 activities were examined in the presence of different concentrations of their inhibitors, lonidamine and etomoxir, to find the concentration of maximum inhibition ([I max]). To assess cell viability and proliferation, dimethylthiazol (MTT) assay was carried out using [I max] for 24, 48, and 72 h on PC3 and LNCaP cells. Apoptosis was determined using annexin-V, caspase-3 activity assay, Hoechst 33258 staining, and evaluation of mitochondrial membrane potential (MMP). Moreover, ATP levels were measured following lonidamine and etomoxir exposure. In addition, to define the impact of exogenous fatty acid on the cell growth and proliferation, CPT-1 activity was evaluated in the presence of palmitate (50 μM). Hexokinase and CPT-1 activities were significantly inhibited by lonidamine [600 μM] and etomoxir [100 μM] in both cell lines. Treatment of the cells with lonidamine [600 μM] resulted in a significant ATP reduction, cell viability and apoptosis, caspase-3 activity elevation, MMP reduction, and appearance of apoptosis-related morphological changes in the cells. In contrast, etomoxir [100 μM] just decreased ATP levels in both cell lines without significant cell death and apoptosis. Compared with glucose (2 g/L), palmitate intensified CPT-1 activity in both cell lines, especially in LNCaP cells. In addition, activity of CPT-1 was higher in LNCaP than PC3 cells. Our results suggest that prostate cancer cells may metabolize glucose as a source of bioenergetic pathways. ATP could also be produced by long-chain fatty acid oxidation. In addition, these data might suggest that LNCaP is more compatible with palmitate.

Keywords

Prostate cancer Apoptosis Caspase-3 ATP Mitochondrial membrane potential LNCaP-FGC-10 PC3 Glycolysis β-Oxidation 

Notes

Acknowledgments

Part of this work was supported by a Ph.D. grant (Rouhallah Najjar Sadeghi) from Tarbiat Modares University and also by the Iranian National Science Foundation (INSF Code: 91046780). The authors thank them for their supports.

Conflicts of interest

None

References

  1. 1.
    Warburg O. Über den stoffwechsel menschlicher tumorzellen. J Mol Med. 1925;4:2396–7.Google Scholar
  2. 2.
    Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006;441:437–43.CrossRefPubMedGoogle Scholar
  3. 3.
    Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res. 2006;66:632–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007;26:299–310.CrossRefPubMedGoogle Scholar
  5. 5.
    Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010;70:2465–75.CrossRefPubMedGoogle Scholar
  7. 7.
    Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS, et al. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther. 2008;7:3546–55.CrossRefPubMedGoogle Scholar
  8. 8.
    Singh G, Lakkis CL, Laucirica R, Epner DE. Regulation of prostate cancer cell division by glucose. J Cell Physiol. 1999;180:431–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis. 2006;9:230–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Res. 2010;30:369–74.PubMedGoogle Scholar
  11. 11.
    Sinha K. Elevated α-methylacyl-CoA racemase enzymatic activity. Am J Pathol2004;164:787-793Google Scholar
  12. 12.
    Rubin M, Zhou M, Dhanasekaran SM. α-Methylacyl-CoA racemase as tissue biomarker of PC. JAMA 2002;287:1662-1670Google Scholar
  13. 13.
    Luo J, Zha S, Gage WR, Dunn TA, et al. α-Methylacyl-CoA racemase; a new molecular marker for prostate cancer. Cancer Res 2002; 62:2220–2226.Google Scholar
  14. 14.
    Jiang Z, W.B.A., Rock K L, Xu Y, Savas L, Khan A, et al., P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001; 25:13971404.Google Scholar
  15. 15.
    Zhou M, Chinnaiyan AM, Kleer CG, Lucas PC, Rubin MA. Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002; 26:926-931.Google Scholar
  16. 16.
    Zha S, Ferdinandusse S, Hicks JL, Denis S, Dunn TA, Wanders RJ, et al. Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. Prostate. 2005;63:316–23.CrossRefPubMedGoogle Scholar
  17. 17.
    Brawer MK. Lonidamine: basic science and rationale for treatment of prostatic proliferative disorders. Rev Urol. 2005;7(7):S21–6.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, de Martino C. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst. 1981;66:497–9.PubMedGoogle Scholar
  19. 19.
    Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, et al. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res. 1981;41:4661–6.PubMedGoogle Scholar
  20. 20.
    Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci. 1977;74:3735–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Xu FY, Taylor WA, Hurd JA, Hatch GM. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells. J Lipid Res. 2003;44:415–23.CrossRefPubMedGoogle Scholar
  22. 22.
    Morillas M, Clotet J, Rubí B, Serra D, Arino J, Hegardt F, et al. Inhibition by etomoxir of rat liver carnitine octanoyltransferase is produced through the co-ordinate interaction with two histidine residues. Biochem J. 2000;351:495–502.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Gerondaes P, Alberti K, Agius L. Interactions of inhibitors of carnitine palmitoyltransferase I and fibrates in cultured hepatocytes. Biochem J. 1988;253:169–73.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Listenberger LL, Ory DS, Schaffer JE. Palmitate-induced apoptosis can occur through a ceramide-independent pathway. J Biol Chem. 2001;276:14890–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Robey RB, Raval BJ, Ma J, Santos AV. Thrombin is a novel regulator of hexokinase activity in mesangial cells. Kidney Int. 2000;57:2308–18.CrossRefPubMedGoogle Scholar
  26. 26.
    Karlic H, Lohninger S, Koeck T, Lohninger A. Dietary l-carnitine stimulates carnitine acyltransferases in the liver of aged rats. J Histochem Cytochem. 2002;50:205–12.CrossRefPubMedGoogle Scholar
  27. 27.
    Salami S, Karami-Tehrani F. Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin Biochem. 2003;36:247–53.CrossRefPubMedGoogle Scholar
  28. 28.
    Perry SW, Norman JP, Barbieri J, Brown EB, Gelbard HA. Mitochondrial membrane potential probes and the proton gradient: a practical usage guide. Biotechniques. 2011;50:98.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Srinivasan S, Stevens M, Wiley JW. Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes. 2000;49:1932–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Epstein JI, Carmichael M, Partin AW. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology. 1995;45:81–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res. 2003;1:707–15.PubMedGoogle Scholar
  32. 32.
    Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M, et al. Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer. 1995;62:216–22.CrossRefPubMedGoogle Scholar
  33. 33.
    Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206:2049–57.CrossRefPubMedGoogle Scholar
  34. 34.
    Kumaravel G, Gandour R, Krueger M, Ramsay R. Comparison of the active sites of the purified carnitine acyltransferases from peroxisomes and mitochondria by using a reaction-intermediate analogue. Biochem J. 1993;294:645–51.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Murthy M, Pande SV. Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc Natl Acad Sci. 1987;84:378–82.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Pimenta AS, Gaidhu MP, Habib S, So M, Fediuc S, Mirpourian M, et al. Prolonged exposure to palmitate impairs fatty acid oxidation despite activation of AMP-activated protein kinase in skeletal muscle cells. J Cell Physiol. 2008;217:478–85.CrossRefPubMedGoogle Scholar
  37. 37.
    Nomura DK, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol. 2011;18:846–56.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Higgins L, Withers H, Garbens A, Love H, Magnoni L, Hayward S, et al. Hypoxia and the metabolic phenotype of prostate cancer cells. Biochim Biophys Acta (BBA)-Bioenerg. 2009;1787:1433–43.CrossRefGoogle Scholar
  39. 39.
    Zaugg K, Yao Y, Reilly PT, Kannan K, Kiarash R, Mason J, et al. Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev. 2011;25:1041–51.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Ruderman NB, Dean D. Malonyl CoA, long chain fatty acyl CoA and insulin resistance in skeletal muscle. J Basic Clin Physiol Pharmacol. 1998;9:295–308.CrossRefPubMedGoogle Scholar
  41. 41.
    Pike LS, Smift AL, Croteau NJ, Ferrick DA, Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta (BBA)-Bioenerg. 2011;1807:726–34.CrossRefGoogle Scholar
  42. 42.
    Kim C, Wong J, Wen J, Wang S, Wang C, Spiering S, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature. 2013;105–10.Google Scholar
  43. 43.
    Lu W, Pelicano H, Huang P. Cancer metabolism: is glutamine sweeter than glucose? Cancer Cell. 2010;18:199–200.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Pouyssegur J, Franchi A, Silvestre P. Relationship between increased aerobic glycolysis and DNA synthesis initiation studied using glycolytic mutant fibroblasts. Nature. 1980;287:445–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Jannière L, Canceill D, Suski C, Kanga S, Dalmais B, Lestini R, et al. Genetic evidence for a link between glycolysis and DNA replication. PLoS One. 2007;2:e447.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Farese RV, Standaert ML, Arnold TP, Yamada K, Musunuru K, Hernandez H, et al. Preferential activation of microsomal diacylglycerol/protein kinase C signaling during glucose treatment (de novo phospholipid synthesis) of rat adipocytes. J Clin Investig. 1994;93:1894–9.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Miele C, Paturzo F, Teperino R, Sakane F, Fiory F, Oriente F, et al. Glucose regulates diacylglycerol intracellular levels and protein kinase C activity by modulating diacylglycerol kinase subcellular localization. J Biol Chem. 2007;282:31835–43.CrossRefPubMedGoogle Scholar
  48. 48.
    Burg JS, Espenshade PJ. Glucose controls phosphoregulation of HMG-CoA reductase through the PP2A-related phosphatase Ppe1 and Insig in fission yeast. J Biol Chem. 2011;111:233452.Google Scholar
  49. 49.
    Mathews EH, Liebenberg L, Pelzer R. High-glycolytic cancers and their interplay with the body’s glucose demand and supply cycle. Med Hypotheses. 2011;76:157–65.CrossRefPubMedGoogle Scholar
  50. 50.
    Zhang A, Wu Y, Lai H, Yew D. Apoptosis—a brief review. Neuroembryol Aging. 2005;3:47–59.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Rouhallah Najjar Sadeghi
    • 1
  • Fatemeh Karami-Tehrani
    • 1
  • Siamak Salami
    • 2
  1. 1.Cancer Research Lab, Department of Clinical BiochemistryFaculty of Medical Sciences, Tarbiat Modares UniversityTehranIran
  2. 2.Clinical Biochemistry Department, Faculty of MedicineShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations